News | Prostate Cancer | December 22, 2016

Phase II for Development of PSMA-targeted Radionuclide Therapy for Prostate Cancer

Cancer Targeted Technology Commences Second Phase of a $2.3M Contract to Develop an Innovative PSMA-targeted Radionuclide Therapy for Prostate Cancer

 

prostate, CT scan, Dave Fornell medical

Cancer Targeted Technology (CTT), a privately-held Seattle-based biotechnology firm focusing on cancer diagnostics and therapeutics, announced that the National Cancer Institute exercised the $2M Phase II option of a Small Business Innovation Research (SBIR) Phase I/II fast-track $2.3M contract to develop a new agent to treat metastatic prostate cancer. The contract develops a promising unique radiotherapeutic drug, CTT1403, that targets Prostate-Specific Membrane Antigen (PSMA). PSMA is over-expressed on prostate cancer and expression increases as the cancer metastasizes and becomes castrate-resistant. CTT’s unique phosphoramidate-based agents, bind irreversibly to PSMA and unlike other agents targeting PSMA, this distinctive mode of binding enhances uptake and internalization by tumor cells leading to increased accumulation of the therapeutic payload and improved efficacy.

In the Phase I $300K portion of the contract, conducted earlier in 2016, CTT successfully synthesized, tested and identified its lead drug, CTT1403. In addition to the PSMA targeting core, CTT1403 incorporates a chemical motif to increase circulation time, increase tumor uptake and decrease any binding to normal tissues. CTT1403, labeled with lutetium-177, demonstrated excellent circulation times in animal studies and cured 75% of mice implanted with human prostate tumors. CTT is working with Carolyn Anderson, M.D., professor of medicine, at University of Pittsburgh, to evaluate CTT1403 in mouse models of prostate cancer.

Anderson commented: "We are excited to continue our collaboration with CTT. The data from the first phase of the contract are promising, and we look forward to furthering this investigation to translate CTT1403 into human studies.”

The Phase II $2M portion advances CTT1403 into Investigational New Drug (IND) enabling studies, including manufacturing, additional pharmacology and safety assessments. These IND studies will support the initial clinical trial in metastatic prostate cancer. CTT’s strategic plan to identify, target, treat and monitor metastatic prostate cancer, employs CTT1403 as a companion therapeutic agent to CTT’s diagnostic Positron Emission Tomography (PET) agent, CTT1057, that commenced clinical trials in November 2016 to image metastatic sites in patients with prostate cancer.

“We have rationally designed CTT1403 to maximize tumor uptake, while minimizing side effects, and the drug is demonstrating exceptional targeting to prostate tumors in animal models,” stated Beatrice Langton-Webster, Ph.D., CEO of CTT and Principal Investigator on the contract. “We were very excited to see substantial increases in survival times in mice implanted with human prostate tumors. CTT1403 holds great promise as a treatment that will result in meaningful increases in life expectancy for men suffering from prostate cancer.”

For more information: www.cancertargetedtechnology.com/

Related Content

Stronger Distribution Networks to Bolster Radiotherapy Patient Positioning Accessories
News | Patient Positioning Radiation Therapy | July 19, 2019
A recent study projects global market revenues for radiotherapy patient positioning accessories will exceed revenues of...
CMS Proposes New Alternative Payment Model for Radiation Oncology
News | Radiation Oncology | July 17, 2019
The Centers for Medicare and Medicaid Services (CMS) issued a proposal for an advanced alternative payment model (APM)...
AAPM 2019 Features More Than 40 Presentations on ViewRay's MRIdian MRI-guided Radiotherapy
News | Image Guided Radiation Therapy (IGRT) | July 16, 2019
ViewRay Inc. announced that the company's MRIdian System is the focus of more than 40 abstracts selected by the...
NorthStar Medical Radioisotopes Completes Construction on Beloit, Wis. Molybdenum-99 Processing Facility
News | Radiopharmaceuticals and Tracers | July 16, 2019
NorthStar Medical Radioisotopes LLC  announced completion of construction on its 20,000-square-foot molybdenum-99 (Mo-...
RaySearch Releases Version 3A of RayCare Oncology Information System
Technology | Oncology Information Management Systems (OIMS) | July 15, 2019
RaySearch has released RayCare 3A, a new version of the next-generation oncology information system (OIS). RayCare is...
IBA Launches Monte Carlo Patient QA for Varian Halcyon at AAPM 2019
Technology | Quality Assurance (QA) | July 10, 2019
IBA announced the launch of the latest functionality of the SciMoCa Monte Carlo Patient QA solution at the 61st annual...
Researchers Use Artificial Intelligence to Deliver Personalized Radiation Therapy
News | Radiation Therapy | July 09, 2019
New Cleveland Clinic-led research shows that artificial intelligence (AI) can use medical scans and health records to...